PAVM PAVMED INC

PAVmed to Present at the 16th Annual Needham Healthcare Conference

PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly differentiated, multi-product medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017, at 10:20 a.m. Eastern time. Dr. Aklog will provide a corporate overview, discuss the company’s innovative business model and review PAVmed’s lead products. The conference is taking place at the Westin New York Grand Central Hotel in New York City on April 4th and 5th.

To access the live webcast of the presentation, please click here. A replay will be available following the presentation.

About PAVmed

PAVmed Inc. (Nasdaq: PAVM, PAVMW) is a highly differentiated, multi-product medical device company employing a unique business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding multi-product pipeline strategy with a view to enhancing and accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs, have attractive regulatory pathways and market opportunities and encompass a broad spectrum of clinical areas including carpal tunnel syndrome (CarpX™), medical infusions (NextFlo™ and NextCath™), interventional radiology (PortIO™ and NextCath), tissue ablation and cardiovascular intervention (Caldus™) and pediatric ear infections (DisappEAR™). The Company intends to further expand its pipeline through engagements with clinician innovators and leading academic medical centers. For further information, please visit www.pavmed.com

EN
28/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PAVMED INC

PAVmed Inc: 1 director

A director at PAVmed Inc maiden bought 250,000 shares at 0.644USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...

 PRESS RELEASE

PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named T...

NEW YORK--(BUSINESS WIRE)-- (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, and its majority-owned subsidiary (Nasdaq: LUCD) (“Lucid”), a commercial-stage cancer prevention medical diagnostics company, today announced that PAVmed and Lucid Chairman & Chief Executive Officer was selected as one of the Top 50 Healthcare Technology CEOs of 2022 by . This press release features multimedia. View the full release here: “I would like to thank The Healthcare Technology Report for this honor,” said Dr. Aklog. “I am so fortunate to work with a rapidly gro...

 PRESS RELEASE

PAVmed PAVmed Provides Business Update and Preliminary First Quarter 2...

NEW YORK--(BUSINESS WIRE)-- (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and presented preliminary financial results for the three months ended March 31, 2022. Conference Call and Webcast A conference call and webcast for today’s business update and first quarter 2022 financial results will take place at ...

 PRESS RELEASE

PAVmed Announces Procedural Update on its Settlement of a Previously D...

PAVmed Announces Procedural Update on its Settlement of a Previously Disclosed Class Action Lawsuit NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced a procedural update on its settlement of a previously disclosed class action lawsuit. As previously disclosed, on January 28, 2021, the Company entered into a term sheet agreement for the settlement of a previously disclosed putative class action lawsuit commenced in November 2020, captioned Spritzer v. PAVmed...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch